Goldman Sachs Group Inc Werewolf Therapeutics, Inc. Transaction History
Goldman Sachs Group Inc
- $706 Billion
- Q2 2025
A detailed history of Goldman Sachs Group Inc transactions in Werewolf Therapeutics, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 227,442 shares of HOWL stock, worth $272,930. This represents 0.0% of its overall portfolio holdings.
Number of Shares
227,442
Previous 111,985
103.1%
Holding current value
$272,930
Previous $108,000
128.7%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding HOWL
# of Institutions
66Shares Held
23.6MCall Options Held
0Put Options Held
0-
Ra Capital Management, L.P. Boston, MA6.68MShares$8.02 Million0.16% of portfolio
-
Mpm Asset Management LLC Cambridge, MA4.31MShares$5.17 Million10.84% of portfolio
-
Bio Impact Capital LLC Cambridge, MA2.41MShares$2.89 Million0.51% of portfolio
-
Bank Of America Corp Charlotte, NC2.13MShares$2.55 Million0.0% of portfolio
-
Black Rock Inc. New York, NY1.59MShares$1.91 Million0.0% of portfolio
About Werewolf Therapeutics, Inc.
- Ticker HOWL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 29,529,400
- Market Cap $35.4M
- Description
- Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional ...